PLAINSBORO, N.J., March 29, 2025 /PRNewswire/ -- Novo Nordisk today presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic ® (semaglutide) injection 1 mg in ...

Tripling the weekly dose of semaglutide (Ozempic, Wegovy) resulted in greater weight loss compared with placebo in adults with obesity, both with and without type 2 diabetes, but did not increase the ...

Results of part 1 of the ESSENCE phase 3 trial, published in The New England Journal of Medicine, demonstrated that a greater proportion of patients with MASH achieved resolution of steatohepatitis ...

Discover more about Novo Nordisk’s launch of the company’s now highest dosage of injectable semaglutide, following last ...

The MarketWatch News Department was not involved in the creation of this content. -- Wegovy(R) (semaglutide injection) granted conditional marketing authorization for the treatment of non-cirrhotic ...

Zydus Lifesciences and Lupin have entered into a licensing and supply agreement to co‑market a semaglutide injection in India ...

Zydus Lifesciences on Saturday announced the launch of Semaglutide Injection in India under the brand names SEMAGLYN™, MASHEMA™ and ALTERME™, following patent expiry.

Emcure slashes semaglutide injection price by 55%, prompting potential moves from Abbott to follow suit in India.

A higher 7.2 mg dose of semaglutide led to significantly greater weight loss compared with placebo in adults with obesity, with or without type 2 diabetes. Participants across two randomized trials ...